GlaxoSmithKline
GSK-funded project will print APIs onto tablets
June 14, 2010Manufacturing and Production, Research and Development GlaxoSmithKline, manufacturing, production, tablets
Researchers at GlaxoSmithKline and two UK universities are working on a technology that could allow active pharmaceutical ingredients to be …
GSK acquires Argentine pharma firm
June 11, 2010Sales and Marketing Argentina, GlaxoSmithKline, Latin America, em
GlaxoSmithKline has acquired a leading Argentine pharma firm Laboratorios Phoenix in a move to make further inroads into Latin America. …
GSK signs RNA therapeutics alliance
March 31, 2010Research and Development GlaxoSmithKline, Isis, RNA
GlaxoSmithKline has forged a new strategic alliance with Isis Pharmaceuticals to exploit the specialist company’s expertise in anti-RNA therapeutics. California-based …
Emma Walmsley to head up GSK consumer healthcare
March 23, 2010Sales and Marketing GlaxoSmithKline, appointment, consumer healthcare, sales and marketing
GlaxoSmithKline has appointed Emma Walmsley president, Consumer Healthcare Europe and president designate, Worldwide Consumer Healthcare with effect from 1 May. …
GSK’s Relovair moves into phase III
March 19, 2010Research and Development GlaxoSmithKline, Relovair, Seretide, Theravance, respiratory
GlaxoSmithKline has started phase III asthma trials of Relovair, the respiratory treatment it is developing with San Francisco biopharma firm …
Revolade gets European go ahead
March 15, 2010Sales and Marketing GlaxoSmithKline, Revolade, thrombocytopenia
European regulators have approved GlaxoSmithKline’s Revolade to treat reduced platelet count in patients with a rare blood disorder. Revolade (eltrombopag) …
GSK promotes Jean Stephenne to chairman, biologicals
March 15, 2010Research and Development, Sales and Marketing GlaxoSmithKline, appointment, research and development, sales and marketing
GlaxoSmithKline has appointed Jean Stephenne chairman of GSK Biologicals, the company’s global vaccines division.He is currently president and general manager of …
GSK expands inflammatory alliance
March 12, 2010Research and Development Cellzome, GlaxoSmithKline, rheumatoid arthritis
GlaxoSmithKline has formed a second strategic alliance with Cellzome to research new treatments for inflammatory diseases. GSK will buy into …
GSK Italy workers protest site closure
March 10, 2010Research and Development GlaxoSmithKline, Italy, job cuts
Workers at a GlaxoSmithKline R&D facility in Verona, Italy, have taken to the streets to protest a decision to close …
GSK’s Deidre Connelly named Woman of the Year
February 25, 2010Sales and Marketing GlaxoSmithKline, HBA, appointment, sales and marketing
The Healthcare Businesswomen’s Association has named Deidre Connelly its 2010 Woman of the Year. Connelly is president of North America …
Reports raise fresh Avandia safety questions
February 23, 2010Research and Development, Sales and Marketing Avandia, GlaxoSmithKline, diabetes
GlaxoSmithKline’s troubled diabetes drug Avandia has been hit by fresh reports from the US that it increases the risk of …
GSK appoints Adrian Hodges
February 16, 2010Sales and Marketing GlaxoSmithKline, appointment, industry reputation, sales and marketing
GlaxoSmithKline has appointed Adrian Hodges to head up corporate responsibility and community partnerships. He moves to the pharma company after …
GSK to downsize Harlow R&D site
February 10, 2010Research and Development GlaxoSmithKline, job cuts
GlaxoSmithKline is on the point of making the first job cuts in a round of redundancies designed to save £500 …
GSK appoints Philippe Fauchet president of GSK Japan
February 8, 2010Sales and Marketing GlaxoSmithKline, appointment, sales and marketing
GSK has appointed Philippe Fauchet president of GSK Japan, reporting to to Marc Dunoyer who takes a new role as …
GSK looks to rare diseases research
February 5, 2010Research and Development GlaxoSmithKline, Orphan
GlaxoSmithKline has launched a new specialist unit to research and develop medicines for rare diseases. The company has identified 5,500 …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
